



UNIVERSITY of  
**BRADFORD**

**Library**

# The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Available access to the published online version may require a subscription.

**Copyright statement:** © 2016 Wiley Periodicals, Inc. Full-text reproduced in accordance with the publisher's self-archiving policy. This is the peer reviewed version of the following article: Elies J, Scragg JL, Boyle JP, Gamper N and Peers C (2016) Regulation of the T-type  $\text{Ca}^{2+}$  channel Cav3.2 by hydrogen sulfide: emerging controversies concerning the role of  $\text{H}_2\text{S}$  in nociception. The Journal of Physiology. 594(15): 4119-4129, which has been published in final form at <http://dx.doi.org/10.1113/JP270963>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

**Regulation of the T-type  $\text{Ca}^{2+}$  channel Cav3.2 by hydrogen sulfide: emerging controversies concerning the role of  $\text{H}_2\text{S}$  in nociception**

Jacobo Elies<sup>1</sup>, Jason L Scragg<sup>1</sup>, John P Boyle<sup>1</sup>, Nikita Gamper<sup>2,3</sup> & Chris Peers<sup>1</sup>

**Authors' affiliation**

<sup>1</sup>Faculty of Medicine and Health, University of Leeds, Leeds, UK

<sup>2</sup>Faculty of Biological Sciences, School of Biomedical Sciences, University of Leeds, Leeds, UK

<sup>3</sup>Department of Pharmacology, Hebei Medical University, Shijiazhuang, China

**Key words:** T-type calcium channel, hydrogen sulphide, gasotransmitter, zinc affinity, redox agents, calcium homeostasis, nociception

**Words:** 4095

**Additional information:**

Competing interests: None.

Authors contributions: All authors contributed to the design, development and content of this article.

Funding: This work was supported by grants from the British Heart Foundation (to CP, JPB and JLS), the Medical Research Council (to C.P. and N.G.), and the Hebei Medical University (to N.G.).

This is an Accepted Article that has been peer-reviewed and approved for publication in the The Journal of Physiology, but has yet to undergo copy-editing and proof correction. Please cite this article as an 'Accepted Article'; [doi: 10.1113/JP270963](https://doi.org/10.1113/JP270963).


This article is protected by copyright. All rights reserved.

Chris Peers obtained his BSc in Physiology and his PhD in Pharmacology at the University of London. He was introduced to the world of oxygen sensing as a postdoctoral worker in Oxford, studying ion channels and their oxygen sensitivity in the carotid body with Piers Nye. He then took up a Lectureship at the University of Leeds where he has remained for 25 years. His interests in the effects of hypoxia have extended over the past decade to incorporate more widespread effects of gasotransmitters on ion channels and how this impacts on the cardiovascular system and in neurodegenerative diseases.

Nikita Gamper got his PhD in Physiology at Sechenov Institute of Evolutionary Physiology and Biochemistry (St Petersburg, Russia). After postdoctoral work at Tuebingen University (Germany) and at the University of Texas Health Science Center at San Antonio (USA) he joined Faculty of Biological Sciences at University of Leeds where he studies molecular and cellular mechanisms of nociception. His group investigates regulation of ion channels that control or influence excitability of peripheral 'pain' neurons; the group is also interested in the modulation of different neuronal ion channels by G protein coupled receptors (GPRs) and in GPCR signalling networks of sensory neurones.

Jacobo Elías studied BSc Pharmacy and completed his PhD at the Department of Pharmacology of the University of Santiago de Compostela, Spain. In 2009 he joined Professor Chris Peers' group at the University of Leeds as a postdoctoral research assistant. Since then he has been investigating the regulation of voltage-gated ion channels by gasotransmitters in cardiovascular diseases, with special interest in carbon monoxide and hydrogen sulphide and their protective actions on the vasculature.







## **Abstract**

Ion channels represent a large and growing family of target proteins regulated by gasotransmitters such as nitric oxide, carbon monoxide and, as described more recently, hydrogen sulfide. Indeed, many of the biological actions of these gases can be accounted for by their ability to modulate ion channel activity. Here, we report recent evidence that H<sub>2</sub>S is a modulator of low voltage-activated T-type Ca<sup>2+</sup> channels, and discriminates between the different subtypes of T-type Ca<sup>2+</sup> channel in that it selectively modulates Cav3.2, whilst Cav3.1 and Cav3.3 are unaffected. At high concentrations, H<sub>2</sub>S augments Cav3.2 currents, an observation which has led to the suggestion that H<sub>2</sub>S exerts its pro-nociceptive effects via this channel, since Cav3.2 plays a central role in sensory nerve excitability. However, at more physiological concentrations, H<sub>2</sub>S is seen to inhibit Cav3.2. This inhibitory action requires the presence of the redox-sensitive, extracellular region of the channel which is responsible for tonic metal ion binding, and which particularly distinguishes this channel isoform from Cav3.1 and 3.3. Further studies indicate that H<sub>2</sub>S may act in a novel manner to alter channel activity by potentiating the zinc sensitivity / affinity of this binding site. This review discusses the different reports of H<sub>2</sub>S modulation of T-type Ca<sup>2+</sup> channels, and how such varying effects may impact on nociception, given the role of this channel in sensory activity. This subject remains controversial, and future studies are required before the impact of T-type Ca<sup>2+</sup> channel modulation by H<sub>2</sub>S might be exploited as a novel approach to pain management.

## **Abbreviations:**

BK<sub>Ca</sub>, Large conductance K<sup>+</sup> channel; CAT, cysteine aminotransferase; CBS, cystathionine β synthase; CSE, cystathionine γ lyase; DAO, D-amino acid oxidase; DRG neuron, dorsal root ganglion neuron; DTT, dithiothreitol; HEK293 cells, K<sub>ATP</sub>, ATP-sensitive K<sup>+</sup> channel; human embryonic kidney cells; LTMR, low threshold mechanoreceptor; MCO, metal-catalysed oxidation; 3-MST, 3-mercaptopyruvate sulfurtransferase; NMDAR, N-methyl-D-aspartate receptor; RMP, resting membrane potential; TPEN, N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine; TRP, Transient receptor potential channels.

## Introduction

Ion channel activity is central to a vast and diverse array of cellular functions in both excitable and non-excitable cell types. They control, for example, gene expression, apoptosis, proliferation, contractility, fluid transport, exocytosis, excitability and action potential propagation. It is therefore unsurprising that the number of genes encoding ion channel proteins (either the pore-forming proteins or auxiliary subunits) runs into the hundreds. This diversity is further increased by splice variation and also the fact that subunits of different channel types can form functional channels by combining with other (albeit related) subunits to form heteromeric complexes. Of the many functions regulated by ion channels one of the most important is the control of  $[Ca^{2+}]_i$  as this ion is a ubiquitous intracellular signalling molecule that mediates many of the ways in which channels influence the above-mentioned fundamental cellular functions (Berridge *et al.*, 2003; Clapham, 2007). Here, we discuss recently discovered new modes of regulation of one specific class of  $Ca^{2+}$  channel, the voltage-gated T-type  $Ca^{2+}$  channel.

Tailoring ion channel activity to serve specific and often co-ordinated roles requires not only the availability of multiple channel types, but also that they can be dynamically regulated. This can occur by a plethora of means; for example by coupling to specific G-proteins and via numerous post-translational modifications including phosphorylation, ubiquitination, sumoylation, nitrosylation, sulfhydration and S-acylation (Rajan *et al.*, 2005; Lipscombe *et al.*, 2013; Gonzalez *et al.*, 2009; Mustafa *et al.*, 2011; Shipston, 2014). Such modifications can regulate ion channel trafficking and membrane insertion, as well as ongoing activity. In recent years, it has become apparent that ion channels are also modulated by endogenously generated, biologically active gases, often termed gasotransmitters; such as nitric oxide, carbon monoxide and hydrogen sulfide (NO, CO and  $H_2S$  respectively). The roles of these gases, especially NO, in diverse physiological and pathological settings have in many instances been long-established, but the concept that they represent a new class of ion channel regulators is currently emerging (Wilkinson & Kemp, 2011; Peers *et al.*, 2012; Peers *et al.*, 2014). In this article, we focus on  $H_2S$  specifically as a modulator of voltage-gated T-type  $Ca^{2+}$  channels.

## **T-type Ca<sup>2+</sup> channels**

When first described at the single channel level, this class of voltage-gated Ca<sup>2+</sup> channel was named “T-type” since members had a relatively tiny conductance and gave rise to transient currents (Nowycky *et al.*, 1985). These channels are also distinguished from other voltage-gated Ca<sup>2+</sup> channels by their rapid activation, slow deactivation and very negative activation thresholds, as low as -60mV or even below (Carbone & Lux, 1984; Perez-Reyes, 2003; Iftinca & Zamponi, 2009). Example currents are shown in Fig. 1A, and a typical current-voltage relationship is presented in Fig. 1B. Owing to this low threshold for activation, they also may display a significant window current (i.e. display tonic activity; Fig. 1C, arrowed) at potentials close to the resting membrane potential (RMP), and so can provide a sustained route for Ca<sup>2+</sup> entry into resting cells (exemplified in Fig. 1D) and also contribute to setting the RMP (Perez-Reyes, 2003). Three genes, *CACNA1G*, *CACNA1H* and *CACNA1I* give rise to pore-forming  $\alpha$ -subunits of T-type Ca<sup>2+</sup> channels, which are nowadays referred to respectively as Cav3.1-3.3 (Catterall *et al.*, 2005), with Cav3.3 showing relatively slower activation and inactivation kinetics than Cav3.1 or Cav3.2 (Fig. 1A). Heterologous expression of individual Cav3  $\alpha$ -subunits gives rise to currents which closely resemble native T-type Ca<sup>2+</sup> currents, suggesting that auxiliary subunits are not required for assembly of functional Ca<sup>2+</sup> channels, although other channel properties and trafficking may indeed be affected by the auxiliary subunits (Dolphin *et al.*, 1999).

T-type Ca<sup>2+</sup> channels are widely distributed, but their physiological functions have sometimes proved difficult to resolve. This is certainly true in vascular smooth muscle cells (VSMCs), where Cav3.1 and Cav3.2 are expressed. Numerous attempts have failed to record “classic” T-type Ca<sup>2+</sup> channel activity in VSMCs (reviewed in (Kuo *et al.*, 2011; Kuo *et al.*, 2014)). Recent studies suggest this is because VSMCs primarily express T-type Ca<sup>2+</sup> channel splice variants which do not activate at the low voltages normally associated with T-type Ca<sup>2+</sup> channels. Instead, they activate over more depolarised voltage ranges as are observed for L-type Ca<sup>2+</sup> channels. Splice variation accounting for these differences occurs in Cav3.1 (and similarly in Cav3.2) primarily around exons 25 and 26, corresponding to the intracellular linker region between domains III and IV (Chemin *et al.*, 2001; Emerick *et al.*, 2006; Latour *et al.*, 2004). Four variants have been identified, termed 25a, 25b, 25bc and 25ac, with variant 25bc predominating in both the juvenile and mature systemic vasculature. These variants all contribute to vasomotor tone (Kuo *et al.*, 2011; Kuo *et al.*, 2014), and



may also have a pacemaker role, controlling slow  $\text{Ca}^{2+}$  waves and contractile oscillations (Cribbs, 2006).

Despite continued uncertainty around the physiological roles of T-type  $\text{Ca}^{2+}$  channels in the vasculature, it appears that in several vascular diseases the influence of T-type  $\text{Ca}^{2+}$  channels, particularly Cav3.1, becomes more prominent. Their increased expression and activity appears to be instrumental in pathological vascular remodelling in both the systemic and pulmonary circulation, providing a route for  $\text{Ca}^{2+}$  entry which is required for proliferation (Tzeng *et al.*, 2012;Chevalier *et al.*, 2014). Interestingly, numerous cancers also rely on the expression of T-type  $\text{Ca}^{2+}$  channels for proliferation, and hence tumour growth (Dziegielewska *et al.*, 2014). These findings suggest that they represent a promising therapeutic target in the treatment of various cancers and cardiovascular diseases.

In the nervous system, T-type  $\text{Ca}^{2+}$  channels serve better defined roles. Thus, for example, in thalamic and corticothalamic neurones T-type  $\text{Ca}^{2+}$  channels are responsible for pacemaker activity and low threshold spikes (Huguenard & Prince, 1994), as illustrated in the cartoon of Fig. 1E. They contribute to “rebound” bursts of spikes following a hyperpolarizing postsynaptic potential. Indeed, evidence suggests that all three isoforms of T-type  $\text{Ca}^{2+}$  channels can contribute to this excitability (Kim *et al.*, 2001;Joksovic *et al.*, 2006;Lee *et al.*, 2014). In the peripheral nervous system, T-type  $\text{Ca}^{2+}$  channels are prominent in somatosensory fibres including small, capsaicin-sensitive (presumed nociceptive) dorsal root ganglion (DRG) neurons (Jevtovic-Todorovic & Todorovic, 2006;Nelson *et al.*, 2006;Rose *et al.*, 2013) as well as in two distinct populations of low-threshold mechanoreceptors (LTMRs), A $\delta$ - and C-LTMRs, innervating skin hair follicles (Francois *et al.*, 2015). Cav3.2 is the dominant form in DRG and may even be the exclusive form in some mechanosensitive neurons (Shin *et al.*, 2003). They can control burst firing in DRG neurons (White *et al.*, 1989) and so strongly influence excitability (Nelson *et al.*, 2005;Nelson *et al.*, 2007a), implying they are of central importance to nociception since stimulus intensity correlates with burst frequency. Indeed, the role of T-type  $\text{Ca}^{2+}$  channels in pain is well recognised and has been covered in depth in several recent reviews (Bourinet *et al.*, 2014;Todorovic & Jevtovic-Todorovic, 2014;Francois *et al.*, 2014;Waxman & Zamponi, 2014;Zamponi *et al.*, 2015). Thus, conditional genetic deletion (Francois *et al.*, 2015), or downregulation of Cav3.2 in DRG using intrathecal injection of antisense oligonucleotides (Bourinet *et al.*, 2005;Messinger *et al.*, 2009) produced strong anti-nociceptive effects in rodent pain models of

neuropathic and inflammatory pain. Conversely, T-type  $\text{Ca}^{2+}$  currents are often increased in pathological conditions associated with chronic pain, such as diabetic neuropathy (Jagodic *et al.*, 2007; Messinger *et al.*, 2009), peripheral nerve injury or inflammation (Jagodic *et al.*, 2008; Garcia-Caballero *et al.*, 2014; Marger *et al.*, 2011). Both the enhancement of channel trafficking (Orestes *et al.*, 2013; Weiss *et al.*, 2013) and enhanced deubiquitination (Garcia-Caballero *et al.*, 2014) were reported as underlying mechanisms for the latter phenomenon.

It is not entirely clear how exactly T-type  $\text{Ca}^{2+}$  channels participate in the nociceptive transmission. Cav3.2 channel expression has been detected in different compartments of afferent fibers including peripheral nociceptive terminals and axons of skin afferents (Rose *et al.*, 2013; Francois *et al.*, 2015), nodes of Ranvier of A $\delta$  fibers (Francois *et al.*, 2015) as well as in the presynaptic terminals of nociceptive fibers in the spinal cord ((Jacus *et al.*, 2012) however, *cf.* Francois *et al.*, 2015). Therefore, multiple mechanisms (or their combinations) are conceivable, including setting the threshold for action potential generation (at the nerve terminals) and propagation (at the nodes of thinly myelinated fibres), supporting burst firing, or indeed promoting synaptic activity at the central terminals of afferent fibres. Finally, since T-type  $\text{Ca}^{2+}$  channels are expressed in skin terminals of low threshold mechanoreceptors, including D-hair cells (Coste *et al.*, 2007; Francois *et al.*, 2015), a more direct role of T-type  $\text{Ca}^{2+}$  channels in mechanotransduction also cannot be excluded.

In accordance with strong evidence for the physiological role of T-type  $\text{Ca}^{2+}$  channels in pain, recent data clearly demonstrated that pharmacological inhibition of T-type  $\text{Ca}^{2+}$  channel activity produces strong anti-nociceptive effects in various rodent pain models (Todorovic *et al.*, 2001; Todorovic *et al.*, 2002; Todorovic *et al.*, 2004; Latham *et al.*, 2009). Together with N-type  $\text{Ca}^{2+}$  channels, T-type  $\text{Ca}^{2+}$  channels are clinically validated drug targets for pain (Bourinet *et al.*, 2014). Accordingly, intense search is currently underway for novel pharmacological tools targeting T-type  $\text{Ca}^{2+}$  channel activity. These need to be more selective than widely used blockers such as mibefradil which, despite its ability to inhibit T-type  $\text{Ca}^{2+}$  channels, is not highly selective (Bezprozvanny & Tsien, 1995). This new generation of more selective T-type inhibitors (e.g. TTA-A2, TTA-P2, KYS-05090S) shows promising analgesic properties in animal models of pain (Choe *et al.*, 2011; Francois *et al.*, 2013). Another novel, selective and orally bioavailable T-type  $\text{Ca}^{2+}$  channel blocker, Z944, which showed analgesic activity in animal models of inflammatory and neuropathic pain, is currently being tested in clinical trials as a first-in-class novel oral analgesic (Lee, 2014). Moreover, Zamponi's lab has recently developed small

molecule modulators that prevent deubiquitination of the Cav3.2 channels by the deubiquitinase USP5, which in turn, can prevent channel upregulation in chronic pain conditions (Gadotti *et al.*, 2015).

### **A redox- and Zn<sup>2+</sup>-sensitive 'module' within the Cav3.2 subunit**

Studies in both native DRG neurons and recombinant expression systems have revealed a regulatory site within Cav3.2 which confers high sensitivity to redox agents, distinguishing it functionally from both Cav3.1 and Cav3.3. Thus, for example, T-type Ca<sup>2+</sup> currents recorded in native nociceptive neurones and recombinant Cav3.2 currents are enhanced by reducing agents (dithiothreitol (DTT) or L-cysteine) and inhibited by the oxidising agent 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) (Nelson *et al.*, 2007a). Sensitivity to these agents was exploited in order to demonstrate the importance of Cav3.2 in nociception: hindpaw injections of DTT or L-cysteine induces thermal and mechanical hyperalgesia (Todorovic *et al.*, 2001), and such effects are prevented with the Ca<sup>2+</sup> channel inhibitor mibefradil; furthermore, analgesic effects are observed with DTNB (Todorovic *et al.*, 2001). Such findings were confirmed in a subpopulation of nociceptive neurons expressing high levels of Cav3 channels (Nelson *et al.*, 2005). An important breakthrough in the field was achieved by the joint work of Perez-Reyes' and Lee's groups which allowed the characterization of specific Cav3.2 residues involved in the metal-induced inhibition of the Ca<sup>2+</sup> channel. The redox-sensitive module is located extracellularly, involving interaction of the extracellular IS1-IS2 linker region with the IS3-IS4 linker region (Kang *et al.*, 2010), the latter region containing a histidine residue (H191) which is key to conferring high redox sensitivity to this channel. Intriguingly, the same H191 residue that is involved in modulation of T-type Ca<sup>2+</sup> channel activity by redox mechanisms also mediates T-type Ca<sup>2+</sup> channel inhibition by low (sub-micromolar) concentrations of extracellular Zn<sup>2+</sup> (Kang *et al.*, 2006; Kang *et al.*, 2010). The full Zn<sup>2+</sup> binding site also includes residues that precede H191, namely D189 and G190, as well as the negatively charged residues at the outer portion of the IS2 segment (Kang *et al.*, 2010). It is, as yet, unclear how exactly the redox- and Zn<sup>2+</sup>-mediated modulatory pathways converge at the same site but one hypothesis suggests that H191 may represent a general binding site for transition metals (e.g. iron, copper, zinc) and can be subject to oxidation via a metal-catalysed oxidation (MCO) reaction (Stadtman, 2001; Nelson *et al.*, 2007a). It is conceivable therefore that either binding of metal (e.g. Zn<sup>2+</sup>) or Zn<sup>2+</sup>-independent MCO of H191 may result in a similar inhibition of channel activity. An alternative hypothesis is that oxidative modification (possibly but

not necessarily at H191) can increase the effect of metal binding either by increasing the affinity at the binding site or by enhancing coupling efficiency between the metal binding and channel inhibition. In such a scenario, oxidative modification could result in sensitization of the channel to  $\text{Zn}^{2+}$  (and potentially other transition metals) making the channel sensitive to ambient concentrations in biological fluids. Total  $\text{Zn}^{2+}$  concentration in human plasma is reported to be within the range of 5-20  $\mu\text{M}$  (Moran *et al.*, 2012). Although it is likely that the free  $[\text{Zn}^{2+}]$  is considerably lower, it is still quite plausible that the extracellular free  $[\text{Zn}^{2+}]$  can reach the nanomolar range at which changes in  $\text{Zn}^{2+}$  affinity/sensitivity of Cav3.2 subunits may result in noticeable changes in channel activity. While the exact mechanism of regulation of Cav3.2 activity via the H191-containing regulatory site remains to be elucidated, it is clear that redox modulation is involved in the action on the T-type  $\text{Ca}^{2+}$  channels of some pharmacological agents and physiological signalling cascades including nitrous oxide (Orestes *et al.*, 2011), CO and thioredoxin (Boycott *et al.*, 2013), as well as GABA<sub>B</sub> receptors (Huang *et al.*, 2015).

### H<sub>2</sub>S as a gasotransmitter

H<sub>2</sub>S is regarded as the third 'gasotransmitter', since it is an endogenous, enzymatically-generated, biologically active gas. Emerging evidence indicates that it has widespread physiological and pathophysiological importance throughout the body (Li *et al.*, 2011). Unsurprisingly, therefore, it has received increasing interest as a potential therapeutic target over the past decade or so, as was the case previously for both NO and CO (Leffler *et al.*, 2006; Moore *et al.*, 2003; Szabo, 2007). H<sub>2</sub>S is generated primarily by the action of two widely distributed enzymes, cystathionine  $\gamma$  lyase (CSE) and cystathionine  $\beta$  synthetase (CBS; Fig. 2). Both synthesise the gas from L-cysteine. More recently, the mitochondrially-located 3-mercaptopyruvate sulfurtransferase (3-MST) has also been found to generate H<sub>2</sub>S in both the brain and vasculature (Fig. 2). 3-MST generates H<sub>2</sub>S from 3-mercaptopyruvate which is itself generated by cysteine aminotransferase (CAT; (Kimura, 2010)). Red blood cells can generate H<sub>2</sub>S non-enzymatically from inorganic polysulfides, a finding which has prompted the idea that H<sub>2</sub>S may mediate the beneficial vascular effects of dietary garlic (Benavides *et al.*, 2007). H<sub>2</sub>S is also known to be liberated in a redox- or pH-sensitive manner from sulfur 'stores'; i.e. sulfur bound to proteins in mitochondria or the cytosol (Kimura, 2010). Differential distribution of H<sub>2</sub>S-generating enzymes results in a predomination of CBS in the central nervous system, along with 3-MST (Leffler *et al.*, 2006); whereas CSE is dominant peripherally, generating the

majority of H<sub>2</sub>S elsewhere in the body, including the vasculature. More recently, H<sub>2</sub>S has been shown to be generated from D-cysteine (Fig. 2), particularly in the cerebellum and kidney, via a novel pathway involving 3-MST and D-amino acid oxidase (Shibuya *et al.*, 2013).

### **H<sub>2</sub>S as a regulator of ion channels**

Ion channels (specifically NMDA receptors; (Abe & Kimura, 1996)) were amongst the first family of cellular proteins recognized as being molecular targets of H<sub>2</sub>S. Since then, reports of ion channel regulation by H<sub>2</sub>S have grown rapidly (Peers *et al.*, 2012; Kuksis & Ferguson, 2015; Zhang *et al.*, 2015), as suggested in Fig. 2. It is clear that modulation by H<sub>2</sub>S is not confined to any particular class of ion channels (such as voltage- or ligand-gated channels) or to channels which are selective for specific ions (e.g. K<sup>+</sup>, Na<sup>+</sup>, Ca<sup>2+</sup> or Cl<sup>-</sup>) (Zhang *et al.*, 2015). H<sub>2</sub>S is also known to interfere with a number of intracellular signalling pathways (Wang, 2012), and it is via these pathways that H<sub>2</sub>S, in some cases, modifies ion channel activity. In other cases, direct post-translational modification accounts for its effects. The best studied of these is the vascular smooth muscle ATP-sensitive K<sup>+</sup> channel (K<sub>ATP</sub> channel), which becomes more active when sulfhydrated (i.e. when –SH groups within cysteine residues are altered to –SSH groups). This direct process (also known as persulfidation; see (Paul & Snyder, 2015)) contributes to vasorelaxation and thereby protects against hypertension (Paul & Snyder, 2012; Mustafa *et al.*, 2011).

The list of ion channels regulated by H<sub>2</sub>S is long and continues to grow. However, some areas of contention have arisen along the way. Thus, for example, inhibition by H<sub>2</sub>S of the high-conductance, Ca<sup>2+</sup>-sensitive K<sup>+</sup> channel has been described in detail (Telezhkin *et al.*, 2010), yet others report activation of this channel by H<sub>2</sub>S (Sitdikova *et al.*, 2010; Jackson-Weaver *et al.*, 2013). Similarly, inhibition of L-type Ca<sup>2+</sup> channels in cardiac myocytes (Sun *et al.*, 2008; Avanzato *et al.*, 2014) contrasts with the observed augmentation of L-type Ca<sup>2+</sup> channel activity reported in astrocytes (Nagai *et al.*, 2004). Such discrepancies may have simple explanations, but these need to be identified if H<sub>2</sub>S modulation of ion channels is to be exploited therapeutically. The remainder of this review is focussed on the known pro-algesic effects of H<sub>2</sub>S and considers the recent, conflicting data concerning the role of T-type Ca<sup>2+</sup> channels in this process.

### **H<sub>2</sub>S as a regulator of Cav3.2**

Our group has recently reported an inhibitory effect of micromolar concentrations of H<sub>2</sub>S on recombinant and native T-type Ca<sup>2+</sup> channels in sensory neurons (Elies *et al.*, 2014). Among Cav3 subunits, this effect was selective to Cav3.2 while Cav3.1 and Cav3.3 were insensitive to H<sub>2</sub>S. In agreement with the predominant expression of Cav3.2 subunits in DRG neurons, H<sub>2</sub>S also strongly inhibited endogenous low-voltage activated (LVA) currents in these neurons. Interestingly, the same extracellular histidine residue H191, which is necessary for Cav3.2 modulation by Zn<sup>2+</sup> and redox agents, was also found critical for the effect of H<sub>2</sub>S. Thus, an H191Q mutation in Cav3.2 abolished channel sensitivity to H<sub>2</sub>S and the analogous reciprocal mutation in Cav3.1 (Q172H) conferred sensitivity to H<sub>2</sub>S on this subunit (Elies *et al.*, 2014). It is not entirely clear exactly how redox/Zn<sup>2+</sup>-binding of Cav3.2 is implicated in this H<sub>2</sub>S-mediated effect but one theory is that H<sub>2</sub>S may increase channel sensitivity to extracellular Zn<sup>2+</sup>. Indeed, chelation of ambient Zn<sup>2+</sup> with TPEN (N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine) fully reversed the H<sub>2</sub>S-mediated T-type Ca<sup>2+</sup> channel inhibition. Moreover, pre-treatment with TPEN abolished H<sub>2</sub>S-mediated inhibition when H<sub>2</sub>S was applied in the continued presence of TPEN. However, subsequent washing out of TPEN in the presence of H<sub>2</sub>S allowed the inhibition to commence (Elies *et al.*, 2014). Thus, the action of H<sub>2</sub>S on Cav3.2 seems to depend on ambient Zn<sup>2+</sup>, assumed to be present in extracellular solutions in trace amounts. Indeed, according to our atomic absorption spectroscopy measurements, total Zn<sup>2+</sup> levels can reach micromolar levels in nominally zinc-free laboratory solutions (Huang & Gamper, unpublished); likewise, micromolar concentrations of Zn<sup>2+</sup> in plasma are also reported (Moran *et al.*, 2012). While levels of free Zn<sup>2+</sup> are likely to be much lower as compared to the total zinc, it is still likely that this metal is present in the extracellular milieu at levels sufficient to affect channel activity. We hypothesize that the action of H<sub>2</sub>S results in the potentiation of channel inhibition by such ambient Zn<sup>2+</sup>, via a mechanism which may share commonalities with the redox modulation of Cav3.2 (see Abstract Figure).

Although our data strongly suggest that H<sub>2</sub>S inhibits Cav3.2 and the endogenous T-type Ca<sup>2+</sup> currents in DRG neurons, there is an alternative theory suggesting that H<sub>2</sub>S augments T-type Ca<sup>2+</sup> currents, possibly by chelating Zn<sup>2+</sup>, and that this augmentation underlies the pro-algesic actions of this gasotransmitter (Matsunami *et al.*, 2011; Kawabata *et al.*, 2007; Takahashi *et al.*, 2010; Maeda *et al.*, 2009). Thus, injection of the H<sub>2</sub>S-donor NaHS into the rat hindpaw produced hyperalgesia which was abolished by the oxidizing agent DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) and by the pharmacological inhibition of T-type Ca<sup>2+</sup> channels (Kawabata *et al.*, 2007). Inhibition of endogenous

H<sub>2</sub>S production also produced an anti-algesic effect. This and other studies by the same group led them to conclude that H<sub>2</sub>S could activate or “sensitize” Cav3.2 channels in order to account for its pro-algesic effects (Takahashi *et al.*, 2010; Kawabata *et al.*, 2007). Furthermore, H<sub>2</sub>S-induced colonic pain could be mimicked by chelation of Zn<sup>2+</sup> (Matsunami *et al.*, 2011). Yet, most of the evidence suggesting that pro-algesic effects of H<sub>2</sub>S are mediated by T-type Ca<sup>2+</sup> channel augmentation is somewhat circumstantial and direct electrophysiological evidence is sparse and insubstantial. For example, pre-incubation of NG108-15 cells with 1.5 mM NaHS resulted in ~20% augmentation of endogenous T-type Ca<sup>2+</sup> current while at 0.5mM the effect was not significant (Kawabata *et al.*, 2007). Another study demonstrated that pre-incubation of HEK293 cells exogenously expressing Cav3.2 channels with the CSE inhibitor propargylglycine resulted in a reduction of the current, which was interpreted as tonic augmentation of recombinant Cav3.2 by endogenous H<sub>2</sub>S (Sekiguchi *et al.*, 2014). Interestingly, only in the presence of this inhibitor were currents augmented by NaHS. These experiments are consistent with potential augmentation of T-type Ca<sup>2+</sup> currents by H<sub>2</sub>S but the following has to be taken into account: i) only very high, millimolar concentrations of NaHS were efficacious; ii) due to the experimental protocol used (pre-incubation) these experiments did not directly assess the acute effect of H<sub>2</sub>S on T-type Ca<sup>2+</sup> channel activity.

In our hands, increasing the NaHS concentration to 3mM did augment recombinant Cav3.2 currents, while even higher concentrations were needed to significantly augment native T-type Ca<sup>2+</sup> channel currents in DRG neurons (Elies *et al.*, 2014). These experiments can, to some degree, reconcile conflicting experimental evidence from different laboratories and suggest a dual effect of H<sub>2</sub>S on T-type Ca<sup>2+</sup> channels: H191-mediated inhibition at low (micromolar) concentrations and potentiation (due to an unknown mechanism) at high (several mM) concentrations. It is important to point out, however, that the presence H<sub>2</sub>S at millimolar concentrations in mammalian tissues is highly unlikely. Initial reports estimated plasma H<sub>2</sub>S levels within the range of 20–100 μM (Li and Moore, 2008), but even these values are now regarded as overestimations (Li *et al.*, 2011). Therefore, physiologically relevant concentrations of H<sub>2</sub>S are unlikely to be sufficiently high to produce T-type Ca<sup>2+</sup> channel augmentation. The expected effect of endogenous H<sub>2</sub>S is, therefore, inhibition of T-type Ca<sup>2+</sup> channel currents, at least in cells and tissues that express significant amounts of Cav3.2 (such as sensory neurons). Therefore, the hypothesis that physiological levels of H<sub>2</sub>S can trigger pro-algesic effects via T-type Ca<sup>2+</sup> channel activation appears questionable at present. Furthermore, in our view, it is also unlikely that H<sub>2</sub>S can act as a Zn<sup>2+</sup> chelator (as was suggested by (Matsunami *et al.*, 2011) as i)



chemical properties of H<sub>2</sub>S do not suggest metal chelating properties (e.g. the ability to form polydentate complexes); ii) acute application of H<sub>2</sub>S leads to T-type Ca<sup>2+</sup> channel current inhibition, whereas Zn<sup>2+</sup> chelation with TPEN causes current augmentation (Nelson *et al.*, 2007b; Elies *et al.*, 2014); iii) application of TPEN completely reverses H<sub>2</sub>S-induced T-type Ca<sup>2+</sup> channel inhibition; iv) pre-application of TPEN renders H<sub>2</sub>S unable to inhibit T-type Ca<sup>2+</sup> channels.

At present, whilst it is hard to envisage how the painful / hyperalgesic effects of H<sub>2</sub>S (especially these of endogenously produced H<sub>2</sub>S) can be mediated by its effect on T-type Ca<sup>2+</sup> channels, other possible targets may account for this action. Thus, H<sub>2</sub>S was suggested to produce some of its pro-algesic effects via TRPA1 activation (Andersson *et al.*, 2012; Hsu *et al.*, 2013). Additionally, H<sub>2</sub>S was suggested to inhibit voltage-gated K<sup>+</sup> channels in trigeminal sensory neurons (most likely Kv1.1 and Kv1.4) thus producing depolarizing and excitatory effects (Feng *et al.*, 2013).

### **Conclusions and perspectives**

Tonic H<sub>2</sub>S production clearly impacts a variety of both physiological and pathological processes, and likely does so in part via direct and indirect modulation of ion channel activity. The numerous and diverse pathways that can be modified by H<sub>2</sub>S suggest that interventional control of this gasotransmitter could be therapeutically beneficial (e.g. in the cardiovascular system and peripheral sensory neurones). However, conflicts have arisen and must be resolved. We believe that at least some issues could be rectified if the experimental conditions through which we study the effects of H<sub>2</sub>S are standardised (e.g. preparation of stock solutions of H<sub>2</sub>S donors, flow rates of solutions containing donors, exposure time, and obligatory use of agar bridges for reference electrodes).

Twenty years after the discovery of H<sub>2</sub>S as an endogenously bioactive molecule (Abe & Kimura, 1996), one of the main challenges within the field remains the measurement of absolute concentrations of H<sub>2</sub>S, in real time, both intracellularly and in extracellular compartments. For instance, development of appropriate intracellular fluorescence probes will expand not only the knowledge regarding intracellular concentrations of H<sub>2</sub>S in space and time, but it will also help to correlate experimental data obtained from exogenously-administered H<sub>2</sub>S with experimental data obtained from endogenously-generated H<sub>2</sub>S. Additionally, future research regarding the physiological effects of H<sub>2</sub>S must bear in mind the crosstalk signalling with other gasotransmitters (NO and CO). Only then can we obtain more comprehensive and uniformly acceptable data on

which to build in order to design modulators of  $\text{H}_2\text{S}$  production and signalling for translational benefit.

## Figure legends

### Abstract Figure

Cartoon showing the linear structure of the transmembrane domain I of the Cav3.2 T-type  $\text{Ca}^{2+}$  channel  $\alpha$  subunit. In the 'tonic' channel state (middle), zinc partially occupies a binding site formed by interacting residues (indicated by white dots) present in IS1-IS2 and IS3-IS4 linkers, including H191. Under these conditions, zinc causes tonic inhibition of evoked currents (as illustrated by example current shown below). Chelation of zinc by TPEN (left) augments current amplitudes via relief of tonic zinc inhibition. In the presence of  $\text{H}_2\text{S}$ , zinc affinity appears augmented, leading to increased zinc binding and a reduction in current amplitude.




Figure 1

Properties of T-type  $\text{Ca}^{2+}$  channels. (A) Example currents evoked by step depolarizations applied (according to the protocol shown above each trace) to HEK293 cells expressing each of the 3 classes of T-type  $\text{Ca}^{2+}$  channel, as indicated. Note the relatively slow activation and inactivation of Cav3.3 as compared with Cav3.1 and Cav3.2. (B) Schematic current-voltage relationship typical of T-type  $\text{Ca}^{2+}$  channels; note the low threshold for activation. (C) Superimposition of steady state inactivation plot (solid line) and activation profile (dashed line) typical of T-type  $\text{Ca}^{2+}$  channels. Note the pronounced window current (region of overlap, arrowed). (D) Fluorimetric recording of  $[\text{Ca}^{2+}]_i$  in a Fura-2 loaded HEK293 cell expressing Cav3.2. For the period indicated by the shaded area, the T-type channel blocker mibefradil ( $1\mu\text{M}$ ) was applied, causing a reduction in basal  $[\text{Ca}^{2+}]_i$  (unpublished data). (E) Cartoon of membrane depolarizations evoked by current injections in thalamic neurones. Note the evoked burst activity is almost fully suppressed in cells lacking the T-type channel Cav3.1 (see Kim *et al.*, 2001).





Figure 1

Figure 2.

Hydrogen sulfide synthesis and effector ion channels. Schematic illustrating the synthesis of H<sub>2</sub>S from homocysteine, L- and D-cysteine via enzymes shown in boxes (CBS, cystathionine  $\beta$  synthase; CSE, cystathionine  $\gamma$  lyase; 3-MST, 3-mercaptopyruvate sulfurtransferase; CAT, cysteine aminotransferase; DAO, D-amino acid oxidase). Some of the target ion channels modulated by H<sub>2</sub>S are also indicated (NMDAR, N-methyl-D-aspartate receptor; VGCC, voltage-gated Ca<sup>2+</sup> channel; TRP, Transient receptor potential channel).



## Reference List

Abe K & Kimura H (1996). The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci* **16**, 1066-1071.

Andersson DA, Gentry C, & Bevan S (2012). TRPA1 has a key role in the somatic pro-nociceptive actions of hydrogen sulfide. *PLoS One* **7**, e46917.

Avanzato D, Merlino A, Porrera S, Wang R, Munaron L, & Mancardi D (2014). Role of calcium channels in the protective effect of hydrogen sulfide in rat cardiomyoblasts. *Cell Physiol Biochem* **33**, 1205-1214.

Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Riley-Usmar VM, Doeller JE, & Kraus DW (2007). Hydrogen sulfide mediates the vasoactivity of garlic. *Proc Natl Acad Sci U S A* **104**, 17977-17982.

Berridge MJ, Bootman MD, & Roderick HL (2003). Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol* **4**, 517-529.

Bezprozvanny I & Tsien RW (1995). Voltage-dependent blockade of diverse types of voltage-gated  $\text{Ca}^{2+}$  channels expressed in *Xenopus* oocytes by the  $\text{Ca}^{2+}$  channel antagonist mibefradil (Ro 40-5967). *Mol Pharmacol* **48**, 540-549.

Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, Pages A, McRory J, Snutch TP, Eschalier A, & Nargeot J (2005). Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. *EMBO J* **24**, 315-324.

Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, & Zamponi GW (2014). Calcium-permeable ion channels in pain signaling. *Physiol Rev* **94**, 81-140.

Boycott HE, Dallas ML, Elies J, Pettinger L, Boyle JP, Scragg JL, Gamper N, & Peers C (2013). Carbon monoxide inhibition of Cav3.2 T-type  $\text{Ca}^{2+}$  channels reveals tonic modulation by thioredoxin. *FASEB J* **27**, 3395-3407.

Carbone E & Lux HD (1984). A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones. *Nature* **310**, 501-502.

Catterall WA, Perez-Reyes E, Snutch TP, & Striessnig J (2005). International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol Rev* **57**, 411-425.

Chemin J, Monteil A, Bourinet E, Nargeot J, & Lory P (2001). Alternatively spliced  $\alpha(1G)$  (Ca<sub>v</sub>3.1) intracellular loops promote specific T-type  $\text{Ca}^{2+}$  channel gating properties. *Biophys J* **80**, 1238-1250.

Chevalier M, Gilbert G, Roux E, Lory P, Marthan R, Savineau JP, & Quignard JF (2014). T-type calcium channels are involved in hypoxic pulmonary hypertension. *Cardiovasc Res* **103**, 597-606.

Choe W, Messinger RB, Leach E, Eckle VS, Obradovic A, Salajegheh R, Jevtovic-Todorovic V, & Todorovic SM (2011). TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinociceptive agent. *Mol Pharmacol* **80**, 900-910.

Clapham DE (2007). Calcium signaling. *Cell* **131**, 1047-1058.

Coste B, Crest M, & Delmas P (2007). Pharmacological dissection and distribution of NaN/Nav1.9, T-type Ca<sup>2+</sup> currents, and mechanically activated cation currents in different populations of DRG neurons. *J Gen Physiol* **129**, 57-77.

Cribbs LL (2006). T-type Ca<sup>2+</sup> channels in vascular smooth muscle: multiple functions. *Cell Calcium* **40**, 221-230.

Dolphin AC, Wyatt CN, Richards J, Beattie RE, Craig P, Lee J-H, Cribbs LL, Volsen SG, & Perez-Reyes E (1999). The effect of  $\alpha 2\text{-}\delta$  and other accessory subunits on expression and properties of the calcium channel  $\alpha 1\text{G}$ . *J Physiol* **519**, 35-45.

Dziegielewska B, Gray LS, & Dziegielewski J (2014). T-type calcium channels blockers as new tools in cancer therapies. *Pflugers Arch* **466**, 801-810.

Elies J, Scragg JL, Huang S, Dallas ML, Huang D, MacDougall D, Boyle JP, Gamper N, & Peers C (2014). Hydrogen sulfide inhibits Cav3.2 T-type Ca<sup>2+</sup> channels. *FASEB J* **28**, 5376-5387.

Emerick MC, Stein R, Kunze R, McNulty MM, Regan MR, Hanck DA, & Agnew WS (2006). Profiling the array of Ca(v)3.1 variants from the human T-type calcium channel gene CACNA1G: alternative structures, developmental expression, and biophysical variations. *Proteins* **64**, 320-342.

Feng X, Zhou YL, Meng X, Qi FH, Chen W, Jiang X, & Xu GY (2013). Hydrogen sulfide increases excitability through suppression of sustained potassium channel currents of rat trigeminal ganglion neurons. *Mol Pain* **9**, 4.

Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, Uebele VN, Renger JJ, Eschalier A, Ardid D, & Bourinet E (2013). State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. *Pain* **154**, 283-293.

Francois A, Laffray S, Pizzoccaro A, Eschalier A, & Bourinet E (2014). T-type calcium channels in chronic pain: mouse models and specific blockers. *Pflugers Arch* **466**, 707-717.

Francois A, Schuetter N, Laffray S, Sanguesa J, Pizzoccaro A, Dubel S, Mantilleri A, Nargeot J, Noel J, Wood JN, Moqrich A, Pongs O, & Bourinet E (2015). The Low-Threshold Calcium Channel Cav3.2 Determines Low-Threshold Mechanoreceptor Function. *Cell Rep*.

Gadotti VM, Caballero AG, Berger ND, Gladding CM, Chen L, Pfeifer TA, & Zamponi GW (2015). Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain. *Mol Pain* **11**, 12.

Garcia-Caballero A, Gadotti VM, Stemkowski P, Weiss N, Souza IA, Hodgkinson V, Bladen C, Chen L, Hamid J, Pizzoccaro A, Deage M, Francois A, Bourinet E, & Zamponi GW (2014). The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. *Neuron* **83**, 1144-1158.

Gonzalez DR, Treuer A, Sun QA, Stamler JS, & Hare JM (2009). S-Nitrosylation of cardiac ion channels. *J Cardiovasc Pharmacol* **54**, 188-195.

Hsu CC, Lin RL, Lee LY, & Lin YS (2013). Hydrogen sulfide induces hypersensitivity of rat capsaicin-sensitive lung vagal neurons: role of TRPA1 receptors. *Am J Physiol Regul Integr Comp Physiol* **305**, R769-R779.

Huang D, Huang S, Peers C, Du X, Zhang H, & Gamper N (2015). GABA receptors inhibit low-voltage activated and high-voltage activated Ca channels in sensory neurons via distinct mechanisms. *Biochem Biophys Res Commun*.

Huguenard JR & Prince DA (1994). Intrathalamic rhythmicity studied in vitro: nominal T-current modulation causes robust antioscillatory effects. *J Neurosci* **14**, 5485-5502.

Iftinca MC & Zamponi GW (2009). Regulation of neuronal T-type calcium channels. *Trends Pharmacol Sci* **30**, 32-40.

Jackson-Weaver O, Osmond JM, Riddle MA, Naik JS, Gonzalez Bosc LV, Walker BR, & Kanagy NL (2013). Hydrogen sulfide dilates rat mesenteric arteries by activating endothelial large-conductance Ca(2)(+)-activated K(+) channels and smooth muscle Ca(2)(+) sparks. *Am J Physiol Heart Circ Physiol* **304**, H1446-H1454.

Jacus MO, Uebele VN, Renger JJ, & Todorovic SM (2012). Presynaptic Cav3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. *J Neurosci* **32**, 9374-9382.



Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, Su P, Jevtovic-Todorovic V, & Todorovic SM (2008). Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. *J Neurophysiol* **99**, 3151-3156.

Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER, Bayliss DA, Jevtovic-Todorovic V, & Todorovic SM (2007). Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. *J Neurosci* **27**, 3305-3316.

Jevtovic-Todorovic V & Todorovic SM (2006). The role of peripheral T-type calcium channels in pain transmission. *Cell Calcium* **40**, 197-203.

Joksovic PM, Nelson MT, Jevtovic-Todorovic V, Patel MK, Perez-Reyes E, Campbell KP, Chen CC, & Todorovic SM (2006). Cav3.2 is the major molecular substrate for redox regulation of T-type Ca<sup>2+</sup> channels in the rat and mouse thalamus. *J Physiol* **574**, 415-430.

Kang HW, Park JY, Jeong SW, Kim JA, Moon HJ, Perez-Reyes E, & Lee JH (2006). A molecular determinant of nickel inhibition in Cav3.2 T-type calcium channels. *J Biol Chem* **281**, 4823-4830.

Kang HW, Vitko I, Lee SS, Perez-Reyes E, & Lee JH (2010). Structural determinants of the high affinity extracellular zinc binding site on Cav3.2 T-type calcium channels. *J Biol Chem* **285**, 3271-3281.

Kawabata A, Ishiki T, Nagasawa K, Yoshida S, Maeda Y, Takahashi T, Sekiguchi F, Wada T, Ichida S, & Nishikawa H (2007). Hydrogen sulfide as a novel nociceptive messenger. *Pain* **132**, 74-81.

Kim D, Song I, Keum S, Lee T, Jeong MJ, Kim SS, McEnery MW, & Shin HS (2001). Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha(1G) T-type Ca(2+) channels. *Neuron* **31**, 35-45.

Kimura H (2010). Hydrogen sulfide: from brain to gut. *Antioxid Redox Signal* **12**, 1111-1123.

Kuksis M & Ferguson AV (2015). Actions of a hydrogen sulfide donor (NaHS) on transient sodium, persistent sodium, and voltage gated calcium currents in neurons of the subfornical organ. *J Neurophysiol* jn.

Kuo IY, Howitt L, Sandow SL, McFarlane A, Hansen PB, & Hill CE (2014). Role of T-type channels in vasomotor function: team player or chameleon? *Pflugers Arch* **466**, 767-779.

Kuo IY, Wolfle SE, & Hill CE (2011). T-type calcium channels and vascular function: The new kid on the block? *J Physiol* **589**, 783-795.

Latham JR, Pathirathna S, Jagodic MM, Choe WJ, Levin ME, Nelson MT, Lee WY, Krishnan K, Covey DF, Todorovic SM, & Jevtovic-Todorovic V (2009). Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice. *Diabetes* **58**, 2656-2665.

Latour I, Louw DF, Beedle AM, Hamid J, Sutherland GR, & Zamponi GW (2004). Expression of T-type calcium channel splice variants in human glioma. *Glia* **48**, 112-119.

Lee M (2014). Z944: a first in class T-type calcium channel modulator for the treatment of pain. *J Peripher Nerv Syst* **19 Suppl 2**, S11-S12.

Lee SE, Lee J, Latchoumane C, Lee B, Oh SJ, Saud ZA, Park C, Sun N, Cheong E, Chen CC, Choi EJ, Lee CJ, & Shin HS (2014). Rebound burst firing in the reticular thalamus is not essential for pharmacological absence seizures in mice. *Proc Natl Acad Sci U S A* **111**, 11828-11833.

Leffler CW, Parfenova H, Jaggar JH, & Wang R (2006). Carbon monoxide and hydrogen sulfide: gaseous messengers in cerebrovascular circulation. *J Appl Physiol* **100**, 1065-1076.

Li L, Rose P, & Moore PK (2011). Hydrogen sulfide and cell signaling. *Annu Rev Pharmacol Toxicol* **51**, 169-187.

Lipscombe D, Allen SE, & Toro CP (2013). Control of neuronal voltage-gated calcium ion channels from RNA to protein. *Trends Neurosci* **36**, 598-609.

Maeda Y, Aoki Y, Sekiguchi F, Matsunami M, Takahashi T, Nishikawa H, & Kawabata A (2009). Hyperalgesia induced by spinal and peripheral hydrogen sulfide: evidence for involvement of Cav3.2 T-type calcium channels. *Pain* **142**, 127-132.

Marger F, Gelot A, Alloui A, Matricon J, Ferrer JF, Barrere C, Pizzoccaro A, Muller E, Nargeot J, Snutch TP, Eschalier A, Bourinet E, & Ardid D (2011). T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. *Proc Natl Acad Sci U S A* **108**, 11268-11273.

Matsunami M, Kirishi S, Okui T, & Kawabata A (2011). Chelating luminal zinc mimics hydrogen sulfide-evoked colonic pain in mice: possible involvement of T-type calcium channels. *Neuroscience* **181**, 257-264.

Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, Orestes P, Latham JR, Todorovic SM, & Jevtovic-Todorovic V (2009). In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. *Pain* **145**, 184-195.

Moore PK, Bhatia M, & Moolchala S (2003). Hydrogen sulfide: from the smell of the past to the mediator of the future? *Trends Pharmacol Sci* **24**, 609-611.

Moran VH, Stammers AL, Medina MW, Patel S, Dykes F, Souverein OW, Dullemeijer C, Perez-Rodrigo C, Serra-Majem L, Nissensohn M, & Lowe NM (2012). The relationship between zinc intake and serum/plasma zinc concentration in children: a systematic review and dose-response meta-analysis. *Nutrients* **4**, 841-858.

Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi FK, Barrow RK, Wang R, Amzel LM, Berkowitz DE, & Snyder SH (2011). Hydrogen Sulfide as Endothelium-Derived Hyperpolarizing Factor Sulphydrates Potassium Channels. *Circ Res* **109**, 1259-1268.

Nagai Y, Tsugane M, Oka J, & Kimura H (2004). Hydrogen sulfide induces calcium waves in astrocytes. *FASEB J* **18**, 557-559.

Nelson MT, Joksovic PM, Perez-Reyes E, & Todorovic SM (2005). The endogenous redox agent L-cysteine induces T-type Ca<sup>2+</sup> channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors. *J Neurosci* **25**, 8766-8775.

Nelson MT, Joksovic PM, Su P, Kang HW, Van DA, Baumgart JP, David LS, Snutch TP, Barrett PQ, Lee JH, Zorumski CF, Perez-Reyes E, & Todorovic SM (2007a). Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. *J Neurosci* **27**, 12577-12583.

Nelson MT, Todorovic SM, & Perez-Reyes E (2006). The role of T-type calcium channels in epilepsy and pain. *Curr Pharm Des* **12**, 2189-2197.

Nelson MT, Woo J, Kang HW, Vitko I, Barrett PQ, Perez-Reyes E, Lee JH, Shin HS, & Todorovic SM (2007b). Reducing agents sensitize C-type nociceptors by relieving high-affinity zinc inhibition of T-type calcium channels. *J Neurosci* **27**, 8250-8260.

Nowycky MC, Fox AP, & Tsien RW (1985). Three types of neuronal calcium channel with different calcium agonist sensitivity. *Nature* **316**, 440-443.

Orestes P, Bojadzic D, Lee J, Leach E, Salajegheh R, Digruccio MR, Nelson MT, & Todorovic SM (2011). Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway. *J Physiol* **589**, 135-148.

Orestes P, Osuru HP, McIntire WE, Jacus MO, Salajegheh R, Jagodic MM, Choe W, Lee J, Lee SS, Rose KE, Piro N, Digruccio MR, Krishnan K, Covey DF, Lee JH, Barrett PQ, Jevtovic-Todorovic V, & Todorovic SM (2013). Reversal of neuropathic pain in diabetes by targeting glycosylation of Ca(V)3.2 T-type calcium channels. *Diabetes* **62**, 3828-3838.

Paul BD & Snyder SH (2012). H<sub>2</sub>S signalling through protein sulfhydration and beyond. *Nat Rev Mol Cell Biol* **13**, 499-507.

Paul BD & Snyder SH (2015). H<sub>2</sub>S: A Novel Gasotransmitter that Signals by Sulfhydration. *Trends Biochem Sci* **40**, 687-700.

Peers C, Bauer CC, Boyle JP, Scragg JL, & Dallas ML (2012). Modulation of ion channels by hydrogen sulfide. *Antioxid Redox Signal* **17**, 95-105.

Peers C, Boyle JP, Scragg JL, Dallas ML, Al-Owais MM, Hettiarachichi NT, Elies J, Johnson E, Gamper N, & Steele DS (2014). Diverse mechanisms underlying the regulation of ion channels by carbon monoxide. *Br J Pharmacol*.

Perez-Reyes E (2003). Molecular physiology of low-voltage-activated t-type calcium channels. *Physiol Rev* **83**, 117-161.

Rajan S, Plant LD, Rabin ML, Butler MH, & Goldstein SA (2005). Sumoylation silences the plasma membrane leak K<sup>+</sup> channel K2P1. *Cell* **121**, 37-47.

Rose KE, Lunardi N, Boscolo A, Dong X, Erisir A, Jevtovic-Todorovic V, & Todorovic SM (2013). Immunohistological demonstration of CaV3.2 T-type voltage-gated calcium channel expression in soma of dorsal root ganglion neurons and peripheral axons of rat and mouse. *Neuroscience* **250**, 263-274.

Sekiguchi F, Miyamoto Y, Kanaoka D, Ide H, Yoshida S, Ohkubo T, & Kawabata A (2014). Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Cav3.2-expressing HEK293 cells. *Biochem Biophys Res Commun* **445**, 225-229.

Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, Ogasawara Y, Fukui K, Nagahara N, & Kimura H (2013). A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. *Nat Commun* **4**, 1366.

Shin JB, Martinez-Salgado C, Heppenstall PA, & Lewin GR (2003). A T-type calcium channel required for normal function of a mammalian mechanoreceptor. *Nat Neurosci* **6**, 724-730.

Shipston MJ (2014). Ion channel regulation by protein S-acylation. *J Gen Physiol* **143**, 659-678.

Sitdikova GF, Weiger TM, & Hermann A (2010). Hydrogen sulfide increases calcium-activated potassium (BK) channel activity of rat pituitary tumor cells. *Pflugers Arch* **459**, 389-397.

Stadtman ER (2001). Protein oxidation in aging and age-related diseases. *Ann N Y Acad Sci* **928**, 22-38.

Sun YG, Cao YX, Wang WW, Ma SF, Yao T, & Zhu YC (2008). Hydrogen sulphide is an inhibitor of L-type calcium channels and mechanical contraction in rat cardiomyocytes. *Cardiovasc Res* **79**, 632-641.

Szabo C (2007). Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* **6**, 917-935.

Takahashi T, Aoki Y, Okubo K, Maeda Y, Sekiguchi F, Mitani K, Nishikawa H, & Kawabata A (2010). Upregulation of Ca(v)3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. *Pain* **150**, 183-191.

Telezhkin V, Brazier SP, Cayzac SH, Wilkinson WJ, Riccardi D, & Kemp PJ (2010). Mechanism of inhibition by hydrogen sulfide of native and recombinant BK(Ca) channels. *Respir Physiol Neurobiol* **172**, 169-178.

Todorovic SM & Jevtovic-Todorovic V (2014). Targeting of CaV3.2 T-type calcium channels in peripheral sensory neurons for the treatment of painful diabetic neuropathy. *Pflugers Arch* **466**, 701-706.

Todorovic SM, Jevtovic-Todorovic V, Meyenburg A, Mennerick S, Perez-Reyes E, Romano C, Olney JW, & Zorumski CF (2001). Redox modulation of T-type calcium channels in rat peripheral nociceptors. *Neuron* **31**, 75-85.

Todorovic SM, Meyenburg A, & Jevtovic-Todorovic V (2002). Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. *Brain Res* **951**, 336-340.

Todorovic SM, Pathirathna S, Brimelow BC, Jagodic MM, Ko SH, Jiang X, Nilsson KR, Zorumski CF, Covey DF, & Jevtovic-Todorovic V (2004). 5beta-reduced neuroactive steroids are novel voltage-dependent blockers of T-type Ca<sup>2+</sup> channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. *Mol Pharmacol* **66**, 1223-1235.

Tzeng BH, Chen YH, Huang CH, Lin SS, Lee KR, & Chen CC (2012). The Cav3.1 T-type calcium channel is required for neointimal formation in response to vascular injury in mice. *Cardiovasc Res* **96**, 533-542.

Wang R (2012). Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol Rev* **92**, 791-896.

Waxman SG & Zamponi GW (2014). Regulating excitability of peripheral afferents: emerging ion channel targets. *Nat Neurosci* **17**, 153-163.

Weiss N, Black SA, Bladen C, Chen L, & Zamponi GW (2013). Surface expression and function of Cav3.2 T-type calcium channels are controlled by asparagine-linked glycosylation. *Pflugers Arch* **465**, 1159-1170.

White G, Lovinger DM, & Weight FF (1989). Transient low-threshold Ca<sup>2+</sup> current triggers burst firing through an afterdepolarizing potential in an adult mammalian neuron. *Proc Natl Acad Sci U S A* **86**, 6802-6806.

Wilkinson WJ & Kemp PJ (2011). Carbon monoxide: an emerging regulator of ion channels. *J Physiol* **589**, 3055-3062.

Zamponi GW, Striessnig J, Koschak A, & Dolphin AC (2015). The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. *Pharmacol Rev* **67**, 821-870.

Zhang W, Xu C, Yang G, Wu L, & Wang R (2015). Interaction of H<sub>2</sub>S with Calcium Permeable Channels and Transporters. *Oxid Med Cell Longev* **2015**, 323269.